Ozempic and Wegovy Makers Face Lawsuit Over Alleged Side Effects, Including Vision Loss

Drugmakers that produce the popular diabetes and weight-loss medications Ozempic and Wegovy are facing a wave of lawsuits from patients alleging serious side effects that were not adequately disclosed, including sudden and severe vision loss. These legal claims, increasingly consolidated into multidistrict litigation, assert that manufacturers such as Novo Nordisk failed to warn users and doctors about risks potentially linked to the drugs’ active ingredient, semaglutide. The controversy highlights ongoing questions about the balance between widespread use of glucagon-like peptide-1 receptor agonist drugs for metabolic conditions and the full understanding of rare but serious adverse outcomes.

What Patients Are Alleging in the Lawsuits

Many lawsuits filed against Novo Nordisk and other manufacturers claim that Ozempic, marketed for type 2 diabetes, and Wegovy, approved for obesity management, can cause non-arteritic anterior ischemic optic neuropathy, or NAION, which may lead to sudden and irreversible vision loss. Plaintiffs describe the condition as an “eye stroke” that severely damages the optic nerve and significantly impairs sight, sometimes leaving people legally blind or unable to drive. In several complaints, patients allege that they and their physicians were not adequately warned about this risk before starting treatment.

How the Litigation Is Organized

The growing number of cases involving vision loss and other serious side effects has prompted judges to centralize many of the lawsuits in multidistrict litigation in the Eastern District of Pennsylvania to streamline pretrial proceedings. Lawyers have filed hundreds or thousands of related claims, not just about vision loss but also about gastrointestinal injuries such as gastroparesis and bowel obstruction. Centralizing these matters helps courts manage discovery and legal strategy more efficiently, even though each individual claim can still be resolved on its own facts.

Other Alleged Side Effects Under Scrutiny

In addition to vision-related claims, many patients have reported gastrointestinal conditions potentially linked to GLP-1 receptor drugs, including gastroparesis, ileus, and bowel obstructions, which can require hospitalization or surgery. Lawsuits claim that these injuries were not clearly communicated to patients or doctors before people began taking medications such as Wegovy and Ozempic, leaving many without adequate warning of serious health risks. Some plaintiffs are pursuing claims that include failure to warn, negligent misrepresentation, and design defects in the way the medications were developed or marketed.

Plaintiff Arguments on Failure to Warn

A core argument in many of the lawsuits is that manufacturers did not provide sufficient warnings about rare but serious side effects, depriving patients and clinicians of the information necessary to make informed decisions about treatment. Plaintiffs contend that emerging research and post-marketing data indicating potential links to vision loss and gastrointestinal injury should have prompted earlier updates to drug labeling. They argue that without transparent communication about these risks, many would have chosen alternative treatments or monitored symptoms more closely.

Research and Safety Signals

Some scientific studies have examined a possible connection between semaglutide drugs and rare eye conditions such as NAION, suggesting an increased incidence in certain patient groups after extended use compared with other medications. Though these conditions remain uncommon overall, the results have drawn attention from regulators and the medical community because they were not always prominent in initial drug trials. Research into related adverse outcomes continues, and these data are expected to play a role in ongoing legal and medical discussions.

Drugmaker Responses and Legal Defenses

Manufacturers like Novo Nordisk have typically responded to litigation by defending the safety profiles of their products and asserting that warning labels and regulatory disclosures meet legal requirements, arguing that causation between the drugs and rare injuries is not definitively established. Some defendants have moved to dismiss certain claims while continuing to face legal pressure as plaintiffs and courts push forward with multidistrict proceedings. Public statements from pharmaceutical companies stress that these medications have helped many patients manage diabetes and weight, even as the litigation unfolds.

Impact on Patients and the Industry

For patients who allege they suffered serious harm, the lawsuits represent efforts to seek compensation for medical costs, lost wages, and life changes stemming from adverse medical outcomes, including vision impairment and prolonged gastrointestinal illness. The litigation also raises broader questions for doctors, regulators, and the pharmaceutical industry about how potential long-term risks are assessed, monitored, and disclosed after drugs reach the market. As GLP-1 medications remain widely prescribed, healthcare professionals continue to weigh their benefits against the possibility of serious but uncommon side effects.

What Travel and Regulatory Watchdogs Are Saying

While the Food and Drug Administration has approved Ozempic and Wegovy based on evidence of their efficacy for managing diabetes and obesity, regulators and watchdog groups monitor adverse event reports and may update guidance based on new safety data. Some international agencies have flagged rare risks such as NAION as potential side effects to consider among specific populations, urging clinicians to monitor visual symptoms in patients on long-term therapy. These signals contribute to a dynamic safety environment as legal and clinical assessments continue.

Facing Extensive Litigation

In conclusion, manufacturers of Ozempic, Wegovy, and related GLP-1 medications are facing extensive litigation alleging that serious side effects, including sudden vision loss and severe gastrointestinal conditions, were not adequately disclosed to patients and healthcare providers. The consolidation of these claims into multidistrict litigation reflects the growing scale and complexity of these cases, which experts say could shape how pharmaceutical safety warnings are handled in the future. Patients and doctors alike are watching as evidence, research, and legal arguments continue to unfold in what may be one of the most significant pharmaceutical liability disputes of the decade.